Trending Topic

roflilumast foam
5 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The FDA recently approved roflumilast 0.3% foam for the treatment of plaque psoriasis of the scalp and body in both adolescents and adults. To better understand how this newly approved therapy fits into clinical practice, what the data show and which patients are likely to benefit, we spoke with Dr Jennifer Soung (Harbor University of California, Los Angeles and Southern California Dermatology, Santa Ana, CA, USA), a key investigator on the phase 3 ARRECTOR trial.

2024 AAD ANNUAL MEETING American Academy of Dermatology

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Feb 9th 2024

San Diego Skyline

We’re looking forward to the upcoming 2024 AAD Annual Meeting which is taking place in San Diego between 8-12 March 2024. 

Promising attendees an opportunity to explore the latest technologies, treatments and products in the field of dermatology, we are excited to provide independent, expert video coverage of key data.

You can sign-up here to receive our AAD 2024 content, as well as future content, or follow the congress on social media using #AAD2024

Soon we’ll be sharing our exclusive interviews with industry experts, but in the meantime – explore our collection of video interviews from here.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup